Development and material characteristics of glaucoma surgical implants

Qin, Qiyu; Zhang, Chengshou; Yu, Naiji; Jia, Fan; Liu, Xin; Zhang, Qi; Chen, Min; Wang, Kaijun

doi:10.1016/j.aopr.2023.09.001

Cited by 4 publications

(3 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compression testing of ocular samples places ocular tissue compressive moduli generally also in the kPa range (Worthington et al., 2014 ). While the low stiffness of the γCD gels may be well-suited for implantation into the similarly soft tissue of the eye, many types of materials, including metals, silicones and gelatin, have been investigated for ocular implantation suggesting that a range of mechanical properties are potentially compatible with this application (Qin et al., 2023 ).…”

Section: Resultsmentioning

confidence: 99%

γ-Cyclodextrin hydrogel for the sustained release of josamycin for potential ocular application

Huling,

Oschatz,

Lange

et al. 2024

Drug Delivery

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

γ-Cyclodextrin hydrogel for the sustained release of josamycin for potential ocular application

Huling,

Oschatz,

Lange

et al. 2024

Drug Delivery

View full text Add to dashboard Cite

“…The Paul Glaucoma Implant (PGI; Advanced Ophthalmic Innovations PTE. LTD. Singapore) received the Conformité Européenne (CE) mark in Europe in 2018 [14]. The tube has an inner diameter of 0.127 mm, and it is supposed to produce less hypotony, tube exposure, and endothelial cell loss than other tube implants [14].…”

Section: Introductionmentioning

confidence: 99%

“…LTD. Singapore) received the Conformité Européenne (CE) mark in Europe in 2018 [14]. The tube has an inner diameter of 0.127 mm, and it is supposed to produce less hypotony, tube exposure, and endothelial cell loss than other tube implants [14]. The intraluminal 6-0 Prolene suture prevents hypotony in the early postoperative period and allows for subsequent intraocular pressure (IOP) control through extraction during postoperative weeks 8-12 [15,16].…”

Section: Introductionmentioning

confidence: 99%

Paul Glaucoma Implant following Congenital Cataract Surgery in a Pediatric Cohort

Mendoza-Moreira,

Voigt,

Stingl

et al. 2024

JCM

View full text Add to dashboard Cite

Background: The aim of this study was to evaluate the short-term efficacy and safety of the Paul Glaucoma Implant (PGI) in pediatric eyes diagnosed with glaucoma following congenital cataract surgery (GFCS). Methods: A retrospective, single-center, descriptive study was conducted on consecutive children diagnosed with GFCS who underwent PGI implantation between July 2022 and November 2023 at the University Medical Center Mainz. The primary outcome measure was the reduction in IOP at the last follow-up visit. Results: Ten eyes of nine children were included in the study. The mean follow-up time was 7.70 ± 4.22 months (4.68–10.72 months). At the end of the study follow-up, the mean (95% CI) reduction in IOP was −14.8 ± 8.73 mmHg (−8.56 to −21.04 mmHg, p < 0.001). At the last follow-up, 30.0% (3/10) of patients achieved an IOP (intraocular pressure) of ≥6 and ≤21 mmHg with a reduction in IOP of ≥25% without treatment, while 90.0% (9/10) achieved this target IOP regardless of glaucoma medication treatment. The mean number of antiglaucoma medications was significantly reduced from 3.50 (IQR = 1) to 2.0 (IQR = 2, p = 0.01), and the visual acuity logMAR improved from 1.26 ± 0.62 to 1.03 ± 0.48 (p = 0.04). Only one eye experienced numerical hypotony (4 mmHg) without choroidal detachment or anterior chamber shallowing within the first 24 h. No other adverse events were observed during the follow-up period. Conclusions: PGI implantation significantly lowered IOP and the number of antiglaucoma eye drops with a favorable safety profile in children diagnosed with GFCS, thereby achieving a high rate of qualified surgical success in the short term.

show abstract